후박나무 껍질

Safety and Toxicology of Magnolol and Honokiol.

1. Planta Med. 2018 Nov;84(16):1151-1164. doi: 10.1055/a-0642-1966. Epub 2018 Jun 20. Safety and Toxicology of Magnolol and Honokiol. Sarrica A(1), Kirika N(1), Romeo M(2), Salmona M(2), Diomede L(2). Author information: (1)Perfetti Van Melle Spa Lainate, Milan, Italy. (2)Department of Molecular

Nitrogenated honokiol derivatives allosterically modulate GABAA receptors and act as strong partial agonists.

2. Bioorg Med Chem. 2015 Oct 15;23(20):6757-62. doi: 10.1016/j.bmc.2015.08.034. Epub 2015 Aug 28. Nitrogenated honokiol derivatives allosterically modulate GABAA receptors and act as strong partial agonists. Bernaskova M(1), Schoeffmann A(2), Schuehly W(3), Hufner A(1), Baburin I(2), Hering S(2

Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats.

3. Arch Pharm Res. 2009 Sep;32(9):1281-92. doi: 10.1007/s12272-009-1914-6. Epub 2009 Sep 26. Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats. Qiang LQ(1), Wang CP, Wang FM, Pan Y, Yi LT, Zhang X, Kong LD. Author informa

Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice.

4. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):616-24. doi: 10.1016/j.pnpbp.2009.03.001. Epub 2009 Mar 11. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. Yi LT(1), Xu Q, Li YC, Yang L, Kong LD. Author informatio

The impact of chewing gum on halitosis parameters: a systematic review.

5. J Breath Res. 2017 Feb 17;11(1):014001. doi: 10.1088/1752-7163/aa5cc2. The impact of chewing gum on halitosis parameters: a systematic review. Muniz FW, Friedrich SA, Silveira CF, Rösing CK. This study aimed to analyze the impact of chewing gum on halitosis parameters. Three databases were se

Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review.

6. Maturitas. 2014 Aug;78(4):263-76. doi: 10.1016/j.maturitas.2014.05.007. Epub 2014 May 28. Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review. Thomas AJ(1), Ismail R(2), Taylor

Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause.

1. Minerva Ginecol. 2011 Feb;63(1):11-7. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Agosta C(1), Atlante M, Benvenuti C. Author information: (1)Casa di Cura San Clemente, Mantova, Italy. AIM: The aim of this paper was to evaluate the activity of magnolia bark extract added to isoflavones and lactobacilli in menopausal women with typical menopausal symptoms and concomitant borderline psychoaffective and/or sleep alterations, of severity not requiring a psychopharmacological therapy. METHODS: Menopausal women were enrolled in a multicenter, controlled, parallel-group study and randomized to E (isoflavones 60 mg + Lactobacillus sporogenes + calcium and vitamin D3 - Estromineral, Rottapharm Madaus) versus ES (magnolia bark extract + E - Estromineral serena) 1 tablet/night for 12 weeks. RESULTS: In 91 gynecological centers, 634 women were treated (300 with E and 334 with ES), mean age 53.1 years and Body Mass Index (BMI) 25.2 kg/m2; 28% were past hormone replacement therapy HRT users and 3.3% had had a previous breast cancer. Both treatments significantly reduced versus baseline the symptoms tested at 0, 4, 8 and 12 weeks. E and ES showed a similar efficacy on hot flushing, nocturnal sweating with awakenings, palpitations and vaginal dryness. ES was more active on insomnia, irritability, anxiety, depressed mood, asthenia and loss of libido. Woman's well-being and physician's final judgment were positive in >70% in both groups. The rate of adverse events was 1% with E (metrorrhagia, cramps and constipation) and 1.2% with ES (gastralgia, blood loss, constipation and breast tension). CONCLUSION: Isoflavones are effective in improving the classical menopause symptoms. The clinical activity of magnolia bark extract on the relevant psycho-affective symptoms, particularly anxiety, irritability and insomnia, was evident. ES in the mild psychical alterations that can occur in climacterium avoids to run the known dependence risks linked to psychopharmacological agents withdrawals. PMID: 21311416 [Indexed for MEDLINE]

The effect of zinc lactate and magnolia bark extract added tablets on volatile sulfur-containing compounds in the oral cavity.

2. J Clin Dent. 2014;25(3):53-6. The effect of zinc lactate and magnolia bark extract added tablets on volatile sulfur-containing compounds in the oral cavity. Porciani PF, Grandini S, Chazine M. OBJECTIVE: A controlled, clinical, double-blind study was conducted to assess the efficacy of sugar-free tablets containing zinc lactate and magnolia bark extract (MBE) on oral volatile sulfur-containing compounds (VSC) versus placebo tablets for two hours. METHODS: In order to join the study, subjects had to have at least 24 teeth, no report of oral and systemic diseases, and no removable dentures. All 128 eligible participants had to avoid any professional oral hygiene, refrain from taking medicines for two weeks, be not menstruating, and not brush their teeth and tongue, smoke, drink alcohol, coffee or tea, eat onion, garlic, or licorice for a six-hour period before the visit and during the test. Moreover, to join the protocol, they had to show a VSC score of ≥ 75 ppb at the baseline measurement. Each qualified subject was placed in the test or the control group using a table of random numbers. The test tablet (0.7 g) contained 0.17 mg of zinc, in the form of zinc lactate, and 0.84 mg magnolia bark extract; the control tablet was identical, but without these active agents. The OralChroma2 device was utilized to evaluate total oral VSC. Their levels were recorded at baseline, after eight minutes of sucking two tablets in succession, after one hour, and after two hours. Data were analyzed with SPSS software and the level of significance was set at α = 0.05. RESULTS: One hundred subjects completed the trial (50 in the control group and 50 in the test group); 52 men and 48 women, mean age 38. None reported problems linked to zinc lactate or magnolia bark extract. The mean percentage reduction from baseline at the end of eight minutes of tablet sucking was 39% in the control group (p < 0.001) and 62% in the test group (p < 0.001); one hour later it was 6% in the control group and 30% in the test group (p < 0.001), and two hours later it was 2% in the control group and 18% in the test group (p < 0.001). The comparisons between the two groups after baseline adjustment showed a statistically significant difference in reductions of VSC between the test and the control tablets at the end of the sucking period (p < 0.01), after one hour (p < 0.001), and after two hours (p < 0.05). CONCLUSION: Tablets containing zinc lactate and magnolia bark extract can statistically significantly reduce the oral VSC levels for over two hours and were statistically significantly more effective than a control tablet. PMID: 26054178 [Indexed for MEDLINE]

The effect of zinc acetate and magnolia bark extract added to chewing gum on volatile sulfur-containing compounds in the oral cavity.

3. J Clin Dent. 2012;23(3):76-9. The effect of zinc acetate and magnolia bark extract added to chewing gum on volatile sulfur-containing compounds in the oral cavity. Porciani PF(1), Grandini S. Author information: (1)University of Siena, Tuscan School of Dental Medicine, Siena, Italy. piercateadsl@libero.it OBJECTIVE: A controlled, clinical, double-blind study was conducted to assess the efficacy of a sugar-free chewing gum containing zinc acetate and magnolia bark extract (MBE) on oral volatile sulfur-containing compounds (VSC) versus a placebo sugar-free chewing gum for two hours. METHODS: To participate in the study, subjects had to have at least 24 of their teeth, no report of oral and systemic diseases, and no removable dentures. All 168 eligible participants had to avoid any professional oral hygiene, refrain from taking medicine for two weeks, and not be menstruating. They were also instructed not to brush their teeth and tongue, smoke, drink alcohol, or eat onion, garlic, or licorice for the six-hour period before the visit and during the test. Moreover, to join the protocol, they had to show a VSC score of > or = 75 ppb at the baseline measurement. One-hundred and twenty-three subjects (67 men and 56 women, mean age 37) met the criteria at baseline and were entered into either the test or control group by assignment from a table of randomized numbers. The test chewing gum (2.23 g) contained zinc acetate 0.012% and magnolia bark extract 0.15% in weight; the control gum was equivalent without these active agents. The OralChroma device was utilized to evaluate total oral VSC. Their levels were recorded at baseline, after ten minutes of mastication, after one hour, and after two hours. Data were analyzed with SPSS software and the level of significance was set at alpha = 0.05. RESULTS: One-hundred and twenty-three subjects completed the trial (62 in the control group and 61 in the test group); none reported problems linked to zinc acetate or magnolia bark extract. The mean percentage reductions from baseline at the end of the 10-minute chewing were 31.2% in the control group (p < 0.05) and 50.9% in the test group (p < 0.05). One hour later the reductions were 6.9% in the control group and 27.6% in the test group (p < 0.05); two hours later the reductions were 2.3% in the control group and 13.6% in the test group. The comparison of the two groups after baseline adjustment showed a statistically significant difference (p < 0.05) in VSC reductions between the test and control chewing gums at the end of the mastication period and after one hour. CONCLUSION: Chewing gum containing zinc acetate and magnoliabark extract can significantly reduce the oral VSC levels for more than one hour. Moreover, the test chewing gum reduces oral VSC significantly more than a control chewing gum. PMID: 23210417 [Indexed for MEDLINE]

Effect of a sugar-free chewing gum containing magnolia bark extract on different variables related to caries and gingivitis: a randomized controlled intervention trial.

4. Caries Res. 2011;45(4):393-9. doi: 10.1159/000330234. Epub 2011 Aug 3. Effect of a sugar-free chewing gum containing magnolia bark extract on different variables related to caries and gingivitis: a randomized controlled intervention trial. Campus G(1), Cagetti MG, Cocco F, Sale S, Sacco G, Strohmenger L, Lingström P. Author information: (1)Dental Institutet, University of Sassari, Sassari, Italy. gcampus@uniss.it The effect of magnolia bark extract (MBE) on different variables related to caries and gingivitis administered daily through a sugar-free chewing gum was evaluated. The study was performed with healthy adult volunteers at high risk for caries as a randomized double-blind interventional study. 120 subjects with a salivary mutans streptococci (MS) concentration ≥10(5) CFU/ml and presence of bleeding on probing >25% were enrolled and divided into three groups: magnolia, xylitol and control. The study design included examinations at baseline, after 7 days, after 30 days of gum use and 7 days after the end of gum use. Plaque pH was assessed using the strip method following a sucrose challenge. Area under the curve (AUC(5.7) and AUC(6.2)) was recorded. Whole saliva was collected and the number of salivary MS (CFU/ml) was counted. Bleeding on probing was recorded as a proxy of dental plaque. Data were analyzed using ANOVA repeated measures. Magnolia gum significantly reduced plaque acidogenicity, MS salivary concentration and gingival bleeding compared to xylitol and control gums. Subjects from the magnolia and xylitol groups showed both MS concentration (p = 0.01 and 0.06, respectively) and AUC(5.7) (p = 0.01 and 0.04, respectively) to be significantly lower compared to baseline. Thirty-day use of a chewing gum containing MBE showed beneficial effects on oral health, including reduction of salivary MS, plaque acidogenicity and bleeding on probing. Copyright © 2011 S. Karger AG, Basel. DOI: 10.1159/000330234 PMID: 21822018 [Indexed for MEDLINE]

[Application of dannang recipe no. 2 in the perioperative stage of laparoscopic cholecystectomy].

5. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Dec;28(12):1090-2. [Application of dannang recipe no. 2 in the perioperative stage of laparoscopic cholecystectomy]. [Article in Chinese] Xu L(1), Jiang J, Du FZ. Author information: (1)General Surgery Department, Traditional Chinese Medicine Hospital of Xiamen City, Fujian. xlxlxlxl0806@126.com OBJECTIVE: To explore the significance of application of Dannang Recipe No. 2 (DNR2), a Chinese herbal preparation, in the perioperative period of laparoscopic cholecystectomy (LC). METHODS: Three hundred and sixty patients with LC were randomly assigned to two groups, 180 in each group. The treatment group was treated with DNR2 in the perioperative period, one dose of the recipe composed of aucklandia root 10 g, red peony root 15 g, giant knotweed rhizome 10 g, scutellaria root 10 g, honeysuckle flower 15 g, forsythia fruit 10 g, rhubarb 9 g, immature bitter orange 10 g, magnolia bark 10 g, peach kernel 10 g, red sage root 20 g and licorice root 4 g, which was boiled with water and taken one dose per day, starting from the previous night of operation. The control group was treated by antibiotic with Ceftizoxime sodium 2.0 g or Levofloxacin 200 mg via intravenous dripping once 0.5 h before operation preventively and 1-3 days after operation according to patients' condition. The indexes, including recovery time of borborygmus, gas elimination and defecation, post-operation body temperature, days needing fluid transfusion, hospitalization time, incidence of infectious complication, as well as the white blood cell counting (WBC) and serum C-reactive protein (CRP) before and after operation, were analyzed and compared between groups. RESULTS: The recovery time of borborygmus, gas elimination and defecation were shorter in the treatment group as compared with that in the control group (10.42 +/- 4.38 h vs. 17.11 +/- 6.25 h, 15.60 +/- 5.03 h vs. 32.74 +/- 9.43 h and 38.81 +/- 9.87 h vs. 56.09 +/- 11.00 h, respectively) and all the other indexes were better in the treatment group than those in the control group, showing significant difference (P < 0.01 or P < 0.05), except the incidence of postoperative infectious complication, it was similar in the two groups. CONCLUSION: Application of DNR2 in perioperative stage of laparoscopic cholecystectomy can effectively promote the recovery of postoperative gastrointestinal motility and suppress the occurrence of acute inflammation. PMID: 19317164 [Indexed for MEDLINE]

Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause.

6. Minerva Ginecol. 2006 Aug;58(4):323-34. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause. Mucci M(1), Carraro C, Mancino P, Monti M, Papadia LS, Volpini G, Benvenuti C. Author information: (1)Obstetric and Gynaecology Surgical Unit, Civil Hospital, Ortona, Chieti, Italy. manuelamucci@tiscalinet.it AIM: Affective and behavioural disorders possibly concomitant to the vasomotor menopausal symptoms worsen quality of life. A rational formulation containing soy isoflavones (60 mg), lactobacilli (500 millions spores), calcium (141 mg) and vitamin D3 (5 microg) was added of Magnolia bark extract (60 mg) and magnesium (50 mg) (Estromineral serena, ES). The Magnolia extract active principles interact with GABA system and exhibit a sedative central action. Magnesium intervenes in enzymatic reactions of the energetic metabolism and protects the bone integrity. Aim of this controlled study was to compare the clinical activity and safety of ES versus calcium+vitamin D3 (Ca+D) in menopause. METHODS: A controlled, randomised, multicentre study was carried out in symptomatic menopausal women with sleep or mood alterations. Women received 1 tablet/day of ES or Ca+D for 24 weeks. Symptoms during the treatment and final judgements on efficacy and acceptability were evaluated. RESULTS: Eighty-nine women (44 ES and 45 Ca+D, mean age 53.8 years, in menopause since 56.6 months) participated to the study. Flushing, nocturnal sweating, palpitations, insomnia, asthenia, anxiety, mood depression, irritability, vaginal dryness, dyspareunia, and libido loss, significantly decreased in severity and frequency during ES versus Ca+D treatment even since the fourth week. Woman wellbeing (good/very good 66.7% vs 20%) judgement on efficacy (72.7% vs 17.1%) and acceptability (93.9% vs 31.4%) were significantly better for ES. CONCLUSIONS: The controlled study showed the efficacy of Magnolia extract and magnesium on psycho-affective and sleep disturbances in menopause, in addition to the effects of isoflavones on vasomotor symptoms. A global natural approach to menopause with ES evidenced its therapeutic usefulness and safety. PMID: 16957676 [Indexed for MEDLINE]